Skeletal mineralization: mechanisms and diseases

키워드

참고문헌 (63)

1. Young MF, "Skeletal biology: where matrix meets mineral", Matrix Biol, 52-54, pp.1~6 (2016)
2. Fukumoto S, "Pathogenesis and diagnostic criteria for rickets and osteomalacia--proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society", J Bone Miner Metab, 33, pp.467~473 (2015)
3. Millán JL, "What can we learn about the neural functions of TNAP from studies on other organs and tissues?", Subcell Biochem, 76, pp.155~166 (2015)
4. Whyte MP, "Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment", Nat Rev Endocrinol, 12, pp.233~246 (2016)
5. Millán JL, "The role of phosphatases in the initiation of skeletal mineralization", Calcif Tissue Int, 93, pp.299~306 (2013)
6. Michigami T, "Roles of phosphate in skeleton", Front Endocrinol (Lausanne), 10, pp.180~ (2019)
7. Solomon DH, "Inorganic phosphate transport in matrix vesicles from bovine articular cartilage", Acta Physiol (Oxf), 190, pp.119~125 (2007)
8. Yadav MC, "Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification", J Bone Miner Res, 26, pp.286~297 (2011)
9. Yadav MC, "Skeletal mineralization deficits and impaired biogenesis and function of chondrocyte-derived matrix vesicles in phospho1(-", -) and phospho1, J Bone Miner Res, pp.2016, 31[DOI]
10. Goltzman D, "Physiology of the calcium-parathyroid hormone-vitamin D axis", Front Horm Res, 50, pp.1~13 (2018)
11. Christakos S, "Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects", Physiol Rev, 96, pp.365~408 (2016)
12. Munns CF, "Global consensus recommendations on prevention and management of nutritional rickets", J Clin Endocrinol Metab, 101, pp.394~415 (2016)
13. "Endocr J", 2017, 1~6
14. Michigami T, "Phosphate as a signaling molecule and its sensing mechanism", Physiol Rev, 98, pp.2317~2348 (2018)
15. Mitchell HH, "The chemical composition of the adult human body and its bearing on the biochemistry of growth", J Biol Chem, 158, pp.625~637 (1945)
16. Murer H, "Transcellular transport of calcium and inorganic phosphate in the small intestinal epithelium", Am J Physiol, 240, pp.G409~G416 (1981)
17. Sabbagh Y, "Intestinal npt2b plays a major role in phosphate absorption and homeostasis", J Am Soc Nephrol, 20, pp.2348~2358 (2009)
18. Capuano P, "Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptorand 1alphaOHase-deficient mice", Am J Physiol Cell Physiol, 288, pp.C429~C434 (2005)
19. Beck L, "Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities", Proc Natl Acad Sci U S A, 95, pp.5372~5377 (1998)
20. Segawa H, "Type IIc sodium-dependent phosphate transporter regulates calcium metabolism", J Am Soc Nephrol, 20, pp.104~113 (2009)
21. Bergwitz C, "SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis", Am J Hum Genet, 78, pp.179~192 (2006)
22. Bacic D, "The renal Na+", phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone, 2006, pp.69, 495~503
23. Picard N, "Acute parathyroid hormone differentially regulates renal brush border membrane phosphate cotransporters", Pflugers Arch, 460, pp.677~687 (2010)
24. Kovesdy CP, "Fibroblast growth factor-23: what we know, what we don't know, and what we need to know", Nephrol Dial Transplant, 28, pp.2228~2236 (2013)
25. Goetz R, "Molecular insights into the klothodependent, endocrine mode of action of fibroblast growth factor 19 subfamily members", Mol Cell Biol, 27, pp.3417~3428 (2007)
26. Kurosu H, "Regulation of fibroblast growth factor-23 signaling by klotho", J Biol Chem, 281, pp.6120~6123 (2006)
27. Urakawa I, "Klotho converts canonical FGF receptor into a specific receptor for FGF23", Nature, 444, pp.770~774 (2006)
28. Ben-Dov IZ, "The parathyroid is a target organ for FGF23 in rats", J Clin Invest, 117, pp.4003~4008 (2007)
29. Ohata Y, "Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice", J Bone Miner Res, 29, pp.1627~1638 (2014)
30. Fukumoto S, "Pathogenesis and diagnostic criteria for rickets and osteomalacia - proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society", Endocr J, 62, pp.665~671 (2015)
31. ADHR Consortium, "Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23", Nat Genet, 26, pp.345~348 (2000)
32. Imel EA, "Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans", J Clin Endocrinol Metab, 96, pp.3541~3549 (2011)
33. Farrow EG, "Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice", Proc Natl Acad Sci U S A, 108, pp.E1146~E1155 (2011)
34. "A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium", Nat Genet, 11, pp.130~136 (1995)
35. Feng JQ, "Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism", Nat Genet, 38, pp.1310~1315 (2006)
36. Lorenz-Depiereux B, "DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis", Nat Genet, 38, pp.1248~1250 (2006)
37. Lorenz-Depiereux B, "Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomalrecessive hypophosphatemic rickets", Am J Hum Genet, 86, pp.267~272 (2010)
38. Rutsch F, "Mutations in ENPP1 are associated with 'idiopathic'infantile arterial calcification", Nat Genet, 34, pp.379~381 (2003)
39. Tagliabracci VS, "Secreted kinase phosphorylates extracellular proteins that regulate biomineralization", Science, 336, pp.1150~1153 (2012)
40. Wang X, "Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice", PLoS Genet, 8, pp.e1002708~ (2012)
41. Tagliabracci VS, "Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3glycosylation, and furin proteolysis", Proc Natl Acad Sci U S A, 111, pp.5520~5525 (2014)
42. Takeyari S, "Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome", Bone, 67, pp.56~62 (2014)
43. Rafaelsen SH, "Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification", J Bone Miner Res, 28, pp.1378~1385 (2013)
44. Shimada T, "Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia", Proc Natl Acad Sci U S A, 98, pp.6500~6505 (2001)
45. Miyagawa K, "Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp mice", PLoS One, 9, pp.e93840~ (2014)
46. Bonewald LF, "The amazing osteocyte", J Bone Miner Res, 26, pp.229~238 (2011)
47. Martin A, "Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR)signaling", FASEB J, 25, pp.2551~2562 (2011)
48. Xiao Z, "Osteocyte-specific deletion of Fgfr1 suppresses FGF23", PLoS One, 9, pp.e104154~ (2014)
49. White KE, "Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation", Am J Hum Genet, 76, pp.361~367 (2005)
50. Yamazaki M, "Both FGF23 and extracellular phosphate activate Raf", MEK, J Cell Biochem, pp.2010, 111[DOI]
51. Kimata M, "Signaling of extracellular inorganic phosphate up-regulates cyclin D1 expression in proliferating chondrocytes via the Na+", Pi cotransporter Pit-1 and Raf, ERK pathway, pp.Bone, 2010[DOI]
52. Nishino J, "Extracellular phosphate induces the expression of dentin matrix protein 1 through the FGF receptor in osteoblasts", J Cell Biochem, 118, pp.1151~1163 (2017)
53. Carpenter TO, "A clinician's guide to X-linked hypophosphatemia", J Bone Miner Res, 26, pp.1381~1388 (2011)
54. Whyte MP, "Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia:a multicentre, open-label, phase 2 trial", Lancet Diabetes Endocrinol, 7, pp.189~199 (2019)
55. Mornet E, "Hypophosphatasia", Orphanet J Rare Dis, 2, pp.40~ (2007)
56. Mornet E, "GeneReviews((R))" (1993), University of Washington, Seattle
57. Wenkert D, "Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review)", J Bone Miner Res, 26, pp.2389~2398 (2011)
58. Ozono K, "Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia", J Clin Endocrinol Metab, 81, pp.4458~4461 (1996)
59. Simon-Bouy B, "Hypophosphatasia: molecular testing of 19 prenatal cases and discussion about genetic counseling", Prenat Diagn, 28, pp.993~998 (2008)
60. Michigami T, "Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia", Eur J Pediatr, 164, pp.277~282 (2005)
61. Whyte MP, "Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease", J Pediatr, 101, pp.379~386 (1982)
62. Whyte MP, "Enzyme-replacement therapy in life-threatening hypophosphatasia", N Engl J Med, 366, pp.904~913 (2012)
63. Whyte MP, "Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia", J Clin Endocrinol Metab, 101, pp.334~342 (2016)

관련 논문AI추천